Solomon B.J. Mok T. Kim D.W. et al.

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

N Engl J Med. 371: 2167-2177Rosell R. Carcereny E. Gervais R. et al.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Lancet Oncol. 13: 239-246Shaw A.T. Kim D.W. Nakagawa K. et al.

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

N Engl J Med. 368: 2385-2394Sequist L.V. Yang J.C.H. Yamamoto N. et al.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

J Clin Oncol. 31: 3327-3334Pao W. Miller V.A. Politi K.A. et al.

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain. Liu ET.

PLoS Med. 2: e73Kobayashi S. Boggon T.J. Dayaram T. et al.

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

N Engl J Med. 352: 786-792Hellman S. Weichselbaum R.R.

Oligometastases.

J Clin Oncol. 13: 8-10Lievens Y. Guckenberger M. Gomez D. et al.

Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document.

Radiother Oncol. 148: 157-166Andratschke N. Alheid H. Allgäuer M. et al.

The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases.

BMC Cancer. 18: 283Fleckenstein J. Petroff A. Schäfers H.J. et al.

Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer.

BMC Cancer. 16: 348Hoyer M. Roed H. Sengelov L. et al.

Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma.

Radiother Oncol. 76: 48-53Osti M.F. Carnevale A. Valeriani M. et al.

Clinical outcomes of single dose stereotactic radiotherapy for lung metastases.

Clin Lung Cancer. 14: 699-703

Overview on Clinical Relevance of Intra-Tumor Heterogeneity.

Front Med. 5: 85Rusthoven K.E. Hammerman S.F. Kavanagh B.D. et al.

Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis.

Acta Oncol. 48: 578-583Schmid S. Klingbiel D. Aeppli S. et al.

Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study.

Lung Cancer. 130: 149-155Rheinheimer S. Heussel C.P. Mayer P. et al.

Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 Inhibitors.

Cancers. 12: E1046Navarro-Martín A. Galiana I. Berenguer Frances M. et al.

Preliminary Study of the Effect of Stereotactic Body Radiotherapy (SBRT) on the Immune System in Lung Cancer Patients Unfit for Surgery: Immunophenotyping Analysis.

IJMS. 19: 3963Golden E.B. Demaria S. Schiff P.B. et al.

An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer.

Cancer Immunol Res. 1: 365-372Ettinger D.S. Wood D.E. Aisner D.L. et al.

Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.

J Natl Compr Cancer Netw. 20: 497-530Sahgal A. Roberge D. Schellenberg D. et al.

The Canadian Association of Radiation Oncology scope of practice guidelines for lung, liver and spine stereotactic body radiotherapy.

Clin Oncol. 24: 629-639Theelen W.S.M.E. Chen D. Verma V. et al.

Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials.

Lancet Respir Med. 9: 467-475Schild S.E. Wang X. Bestvina C.M. et al.

Alliance A082002 -a randomized phase II/III trial of modern immunotherapy-based systemic therapy with or without SBRT for PD-L1-negative, advanced non-small cell lung cancer.

Clin Lung Cancer. 23: e317-e320Palma D.A. Olson R. Harrow S. et al.

Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial.

J Clin Oncol. 38: 2830-2838Palma D.A. Olson R. Harrow S. et al.

Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial.

Lancet. 393: 2051-2058Gomez D.R. Blumenschein G.R. Lee J.J. et al.

Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study.

Lancet Oncol. 17: 1672-1682Gomez D.R. Tang C. Zhang J. et al.

Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study.

J Clin Orthod. 37: 1558-1565Iyengar P. Wardak Z. Gerber D.E. et al.

Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.

JAMA Oncol. 4: e173501Shukuya T. Takahashi T. Naito T. et al.

Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure.

Lung Cancer. 74: 457-461Salama J.K. Hasselle M.D. Chmura S.J. et al.

Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease.

Cancer. 118: 2962-2970Chan O.S.H. Lam K.C. Li J.Y.C. et al.

ATOM: A phase II study to assess efficacy of preemptive local ablative therapy to residual oligometastases of NSCLC after EGFR TKI.

Lung Cancer. 142: 41-46Weiss J. Kavanagh B. Deal A. et al.

Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib.

Cancer Treat Res Commun. 19: 100126Iyengar P. Kavanagh B.D. Wardak Z. et al.

Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer.

J Clin Oncol. 32: 3824-3830Tsai C.J. Yang J.T. Guttmann D.M. et al.

Consolidative Use of Radiotherapy to Block (CURB) Oligoprogression ― Interim Analysis of the First Randomized Study of Stereotactic Body Radiotherapy in Patients With Oligoprogressive Metastatic Cancers of the Lung and Breast.

Int J Radiat Oncol Biol Phys. 111: 1325-1326Chan O.S.H. Lee V.H.F. Mok T.S.K. et al.

The Role of Radiotherapy in Epidermal Growth Factor Receptor Mutation-positive Patients with Oligoprogression: A Matched-cohort Analysis.

Clin Oncol. 29: 568-575Wang Y. Li Y. Xia L. et al.

Continued EGFR-TKI with concurrent radiotherapy to improve time to progression (TTP) in patients with locally progressive non-small cell lung cancer (NSCLC) after front-line EGFR-TKI treatment.

Clin Transl Oncol. 20: 366-373Cortellini A. Leonetti A. Catino A. et al.

Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes.

Clin Transl Oncol. 22: 844-851Pastorino U. Buyse M. Friedel G. et al.

Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases.

J Thorac Cardiovasc Surg. 113: 37-49Joosten P.J.M. de Langen A.J. van der Noort V. et al.

The role of surgery in the treatment of oligoprogression after systemic treatment for advanced non-small cell lung cancer.

Lung Cancer. 161: 141-151

Thermal ablation of tumours: biological mechanisms and advances in therapy.

Nat Rev Cancer. 14: 199-208Jiang T. Chu Q. Wang H. et al.

EGFR-TKIs plus local therapy demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases.

Int J Cancer. 144: 2605-2612Ni Y. Liu B. Ye X. et al.

Local Thermal Ablation with Continuous EGFR Tyrosine Kinase Inhibitors for EGFR-Mutant Non-small Cell Lung Cancers that Developed Extra-Central Nervous System (CNS) Oligoprogressive Disease.

Cardiovasc Intervent Radiol. 42: 693-699Horn L. Mansfield A.S. Szczęsna A. et al.

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.

N Engl J Med. 379: 2220-2229Slotman B.J. van Tinteren H. Praag J.O. et al.

Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial.

Lancet. 385: 36-42

Combining Radiotherapy and Immunotherapy in Patients.

() ()

Oligoprogressive Oncogene-addicted Lung Tumours: Does Stereotactic Body Radiotherapy Have a Role? Introducing the HALT Trial.

Clin Oncol. 30: 1-4Jordan E.J. Kim H.R. Arcila M.E. et al.

Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.

Cancer Discov. 7: 596-609Frampton G.M. Ali S.M. Rosenzweig M. et al.

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.

Cancer Discov. 5: 850-859Dall’Olio F.G. Conci N. Rossi G. et al.

Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients – A single centre experience.

Lung Cancer. 149: 5-9Hu C. Wu S. Deng R. et al.

Radiotherapy with continued EGFR-TKIs for oligoprogressive disease in EGFR-mutated non-small cell lung cancer: A real-world study.

Cancer Med. 12: 266-273Katz L.M. Ng V. Wu S.P. et al.

Stereotactic Body Radiation Therapy for the Treatment of Locally Recurrent and Oligoprogressive Non-Small Cell Lung Cancer: A Single Institution Experience.

Front Oncol. 12: 870143Mok F.S.T. Tong M. Loong H.H. et al.

Local ablative radiotherapy on oligo-progression while continued on epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer patients: A longer cohort.

Asia Pac J Clin Oncol. 18: 614-624Kroeze S.G.C. Schaule J. Fritz C. et al.

Metastasis directed stereotactic radiotherapy in NSCLC patients progressing under targeted- or immunotherapy: efficacy and safety reporting from the “TOaSTT” database.

Radiat Oncol. 16: 4Wang Z. Wei L. Li J. et al.

Combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer.

Transl Lung Cancer Res. 10: 4368-4379Buglione M. Jereczek-Fossa B.A. Bonù M.L. et al.

Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic/oligoprogressive non-small cell lung cancer patients: Results of a multi-institutional series of 198 patients treated with “curative” intent.

Lung Cancer. 141: 1-8Friedes C. Mai N. Fu W. et al.

Isolated progression of metastatic lung cancer: Clinical outcomes associated with definitive radiotherapy.

Cancer. 126: 4572-4583Santarpia M. Altavilla G. Borsellino N. et al.

High-dose Radiotherapy for Oligo-progressive NSCLC Receiving EGFR Tyrosine Kinase Inhibitors: Real World Data.

Vivo. 34: 2009-2014Borghetti P. Bonù M.L. Giubbolini R. et al.

Concomitant radiotherapy and TKI in metastatic EGFR- or ALK-mutated non-small cell lung cancer: a multicentric analysis on behalf of AIRO lung cancer study group.

Radiol Med. 124: 662-670Rossi S. Finocchiaro G. Noia V.D. et al.

Survival outcome of tyrosine kinase inhibitors beyond progression in association to radiotherapy in oligoprogressive EGFR-mutant non-small-cell lung cancer.

Future Oncol. 15: 3775-3782Xu Q. Liu H. Meng S. et al.

First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease.

J Cancer. 10: 522-529Merino Lara T. Helou J. Poon I. et al.

Multisite stereotactic body radiotherapy for metastatic non-small-cell lung cancer: Delaying the need to start or change systemic therapy?.

Lung Cancer. 124: 219-226Qiu B. Liang Y. Li Q. et al.

Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non-small-cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation.

Clin Lung Cancer. 18: e369-e373Gan G.N. Weickhardt A.J. Scheier B. et al.

Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib.

Int J Radiat Oncol Biol Phys. 88: 892-898Yu H.A. Sima C.S. Huang J. et al.

Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors.

J Thorac Oncol. 8: 346-351Weickhardt A.J. Scheier B. Burke J.M. et al.

Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.

J Thorac Oncol. 7: 1807-1814